MCID: LNG035
MIFTS: 45

Lung Large Cell Carcinoma

Categories: Cancer diseases, Respiratory diseases, Rare diseases, Neuronal diseases

Aliases & Classifications for Lung Large Cell Carcinoma

MalaCards integrated aliases for Lung Large Cell Carcinoma:

Name: Lung Large Cell Carcinoma 12 15
Large Cell Carcinoma of Lung 12 73
Large Cell Lung Carcinoma 12
Large Cell Lung Cancer 55

Classifications:



External Ids:

Disease Ontology 12 DOID:4556
NCIt 50 C4450
SNOMED-CT 68 254629004
UMLS 73 C0345958

Summaries for Lung Large Cell Carcinoma

MalaCards based summary : Lung Large Cell Carcinoma, also known as large cell carcinoma of lung, is related to large cell carcinoma with rhabdoid phenotype and lung cancer. An important gene associated with Lung Large Cell Carcinoma is ROS1 (ROS Proto-Oncogene 1, Receptor Tyrosine Kinase), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and testes, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Large-cell carcinoma (LCC) is a heterogeneous group of undifferentiated malignant neoplasms that lack... more...

Related Diseases for Lung Large Cell Carcinoma

Graphical network of the top 20 diseases related to Lung Large Cell Carcinoma:



Diseases related to Lung Large Cell Carcinoma

Symptoms & Phenotypes for Lung Large Cell Carcinoma

GenomeRNAi Phenotypes related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

26 (show top 50) (show all 56)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 11.04 EPHA3 MTOR
2 Decreased viability GR00221-A-1 11.04 DDR2 CAMK4 MTOR FGFR1 ROS1 NME1
3 Decreased viability GR00221-A-2 11.04 DDR2 EPHA5 FGFR1 ROS1 NME1 WNK3
4 Decreased viability GR00221-A-3 11.04 EPHA5
5 Decreased viability GR00221-A-4 11.04 DDR2 EPHA3 EPHA5 MTOR WNK3 TTN
6 Decreased viability GR00301-A 11.04 CAMK4 EPHA3
7 Decreased viability GR00342-S-1 11.04 EPHA3 MTOR ROS1 TTN
8 Decreased viability GR00342-S-2 11.04 MTOR
9 Decreased viability GR00342-S-3 11.04 EPHA5 TTN
10 Decreased viability GR00402-S-2 11.04 DDR2 CAMK4 EPHA3 EPHA5 MTOR FGFR1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.35 DDR2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.35 MTOR
13 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.35 MTOR
14 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.35 DDR2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.35 ATR
16 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.35 TRRAP
17 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.35 NME1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.35 CAMK4 WNK3
19 Increased shRNA abundance (Z-score > 2) GR00366-A-13 10.35 NME1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.35 BRSK1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.35 CAMK4
22 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.35 DDR2 MTOR
23 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.35 ATR
24 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.35 NME1 TRRAP
25 Increased shRNA abundance (Z-score > 2) GR00366-A-174 10.35 DDR2
26 Increased shRNA abundance (Z-score > 2) GR00366-A-183 10.35 BRSK1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.35 TRRAP
28 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.35 DDR2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.35 TRRAP
30 Increased shRNA abundance (Z-score > 2) GR00366-A-195 10.35 CAMK4
31 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.35 BRSK1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.35 ATR
33 Increased shRNA abundance (Z-score > 2) GR00366-A-2 10.35 ATR
34 Increased shRNA abundance (Z-score > 2) GR00366-A-24 10.35 DDR2
35 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.35 WNK3
36 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.35 WNK3
37 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.35 DDR2
38 Increased shRNA abundance (Z-score > 2) GR00366-A-4 10.35 BRSK1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.35 MTOR
40 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.35 NME1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.35 CAMK4
42 Increased shRNA abundance (Z-score > 2) GR00366-A-69 10.35 CAMK4 WNK3
43 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.35 BRSK1 ATR
44 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.35 CAMK4 MTOR
45 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.35 DDR2
46 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.35 DDR2 BRSK1 CAMK4 ATR MTOR NME1
47 Increased shRNA abundance (Z-score > 2) GR00366-A-97 10.35 NME1
48 Decreased substrate adherent cell growth GR00193-A-1 10.14 ATR BRSK1 ROS1 TTN
49 Decreased substrate adherent cell growth GR00193-A-2 10.14 MTOR EPHA3 ROS1 TRRAP WNK3
50 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 10.09 BRSK1 CAMK4 ATR FGFR1 EPHA3 MTOR

MGI Mouse Phenotypes related to Lung Large Cell Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.96 TRRAP CAMK4 TTN WNK3 DDR2 EPHA3
2 cardiovascular system MP:0005385 9.92 TTN WNK3 DDR2 EPHA3 FGFR1 MTOR
3 mortality/aging MP:0010768 9.9 CAMK4 TTN DDR2 EPHA3 FGFR1 MTOR
4 nervous system MP:0003631 9.56 BRSK1 CAMK4 DDR2 EPHA5 FGFR1 MTOR
5 normal MP:0002873 9.17 CAMK4 TTN WNK3 FGFR1 MTOR ATR

Drugs & Therapeutics for Lung Large Cell Carcinoma

Drugs for Lung Large Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 131)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
2
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
3
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
4
Everolimus Approved Phase 4 159351-69-6 6442177
5
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
6 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
12 Antibiotics, Antitubercular Phase 4,Phase 1,Phase 2
13 Antifungal Agents Phase 4
14
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
15
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
16
Gefitinib Approved, Investigational Phase 3,Phase 2,Phase 1 184475-35-2 123631
17
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
18
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 60780 44424639
19
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
20
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
21
Celecoxib Approved, Investigational Phase 3,Phase 2 169590-42-5 2662
22
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
23
Cetuximab Approved Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
24
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
25
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 216974-75-3
26
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
27
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
28
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
29
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
30
Tirapazamine Investigational Phase 3,Phase 1 27314-97-2
31
Erlotinib Hydrochloride Phase 3,Phase 2,Phase 1 183319-69-9 176871
32 Folic Acid Antagonists Phase 3,Phase 2,Phase 1
33 Hematinics Phase 3,Phase 2
34 Vitamin B Complex Phase 3,Phase 2,Phase 1
35 Antibodies Phase 2, Phase 3,Phase 3,Phase 1
36 Immunoglobulins Phase 2, Phase 3,Phase 3,Phase 1
37 Antibodies, Monoclonal Phase 2, Phase 3,Phase 3,Phase 1
38 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
39 Antimetabolites Phase 3,Phase 2,Phase 1
40 Antiviral Agents Phase 3,Phase 2,Phase 1
41 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
42 Epoetin alfa Phase 3 113427-24-0
43 Analgesics Phase 3,Phase 2
44 Mitogens Phase 3,Phase 2
45 Cyclooxygenase 2 Inhibitors Phase 3,Phase 2
46 Cyclooxygenase Inhibitors Phase 3,Phase 2
47 Analgesics, Non-Narcotic Phase 3,Phase 2
48 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
49 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
50 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 152)
# Name Status NCT ID Phase Drugs
1 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
2 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
3 Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
4 Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery Completed NCT00003387 Phase 3 carboplatin;chemotherapy;paclitaxel
5 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Completed NCT00021060 Phase 2, Phase 3 paclitaxel;carboplatin
6 Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00020709 Phase 3 cisplatin;docetaxel;etoposide;gefitinib
7 Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00005838 Phase 3 shark cartilage extract AE-941;cisplatin;vinorelbine tartrate;carboplatin;paclitaxel
8 Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Completed NCT00002852 Phase 3 paclitaxel;carboplatin
9 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed Completed NCT00003235 Phase 3 carboplatin;paclitaxel
10 Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer Completed NCT00002550 Phase 3 cisplatin;etoposide
11 Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung Cancer Completed NCT00003831 Phase 3
12 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Completed NCT00049543 Phase 3 gefitinib
13 Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00079287 Phase 3 carboplatin;docetaxel;gemcitabine hydrochloride;paclitaxel;vinorelbine tartrate
14 Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer Completed NCT00028938 Phase 3 carboplatin;paclitaxel
15 Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00002623 Phase 3 carboplatin;cisplatin
16 Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Completed NCT00006484 Phase 3 carboplatin;paclitaxel;tirapazamine
17 Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery Completed NCT00003901 Phase 3
18 Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer Completed NCT00003117 Phase 3 carboplatin;paclitaxel
19 Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer Completed NCT00003685 Phase 3
20 Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer Completed NCT00002823 Phase 3 cisplatin;etoposide;vinblastine sulfate;vindesine;vinorelbine tartrate
21 Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) Recruiting NCT02194738 Phase 3 Crizotinib;Erlotinib Hydrochloride
22 Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients Active, not recruiting NCT00030771 Phase 3 Chemotherapy
23 S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Active, not recruiting NCT00946712 Phase 3 Carboplatin;Paclitaxel
24 Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
25 Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting NCT01107626 Phase 3 pemetrexed disodium
26 Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer Terminated NCT00113386 Phase 3 cisplatin;docetaxel
27 Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer Terminated NCT01041781 Phase 3 carboplatin;celecoxib;gemcitabine hydrochloride;pemetrexed disodium
28 Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer Terminated NCT00004859 Phase 3 carboplatin;paclitaxel;thalidomide
29 Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy Terminated NCT01208064 Phase 2, Phase 3 pazopanib hydrochloride
30 Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer Terminated NCT00863512 Phase 3 cisplatin;docetaxel;gemcitabine hydrochloride;pemetrexed disodium;vinorelbine tartrate
31 Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer Withdrawn NCT00055887 Phase 3 carboplatin;cisplatin;efaproxiral;gemcitabine hydrochloride;paclitaxel;vinorelbine ditartrate
32 Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Withdrawn NCT00054392 Phase 3 carboplatin;gemcitabine hydrochloride;paclitaxel
33 Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer Unknown status NCT00616499 Phase 2 gefitinib
34 Docetaxel Plus Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Unknown status NCT00003562 Phase 2 carboplatin;docetaxel
35 Gemcitabine and Docetaxel in Treating Patients With Inoperable Stage IIIB or Stage IV Non-Small Cell Lung Cancer Unknown status NCT00075517 Phase 2 docetaxel;gemcitabine hydrochloride
36 Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Unknown status NCT00006116 Phase 2 cisplatin;gemcitabine hydrochloride
37 Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT01024712 Phase 2 carboplatin;gefitinib;paclitaxel
38 Docetaxel in Treating Older Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Unknown status NCT00227708 Phase 2 docetaxel
39 Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Unknown status NCT00033722 Phase 2 lometrexol
40 Gemcitabine and Cisplatin Before or After Surgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer Unknown status NCT00398385 Phase 2 cisplatin;gemcitabine hydrochloride
41 Combination Chemotherapy Followed by Surgery in Treating Patients With Non-small Cell Lung Cancer Completed NCT00003231 Phase 2 cisplatin;docetaxel
42 Combination Chemotherapy Followed by Radiation Therapy Before Surgery in Treating Patients With Stage IIIB NSCLC Completed NCT00030810 Phase 2 Taxotere/Cisplatin
43 MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy Completed NCT01294306 Phase 2 Akt Inhibitor MK2206;Erlotinib Hydrochloride
44 S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer Completed NCT00087412 Phase 2 erlotinib hydrochloride
45 Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial). Completed NCT01116219 Phase 2 bevacizumab, pemetrexed, cisplatin
46 Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer Completed NCT00003666 Phase 2 6-hydroxymethylacylfulvene
47 Temozolomide in Treating Patients With Metastatic Non-small Cell Lung Cancer Completed NCT00006877 Phase 2 temozolomide
48 Video-Assisted Surgery Followed by Radiation Therapy in Treating Patients With Stage I Non-small Cell Lung Cancer and Poor Heart and Lung Function Completed NCT00002624 Phase 2
49 Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00411047 Phase 2 gefitinib
50 Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00070486 Phase 2 carboplatin;celecoxib;gemcitabine hydrochloride;zileuton

Search NIH Clinical Center for Lung Large Cell Carcinoma

Genetic Tests for Lung Large Cell Carcinoma

Anatomical Context for Lung Large Cell Carcinoma

MalaCards organs/tissues related to Lung Large Cell Carcinoma:

41
Lung, Brain, Testes, Endothelial, Heart, Lymph Node

Publications for Lung Large Cell Carcinoma

Articles related to Lung Large Cell Carcinoma:

(show all 12)
# Title Authors Year
1
Oxidative stress associates with aggressiveness in lung large-cell carcinoma. ( 25638031 )
2015
2
Large cell carcinoma of lung: On the verge of extinction? ( 25023633 )
2014
3
Rhabdoid large cell carcinoma of lung, with illustrative immunohistochemical and molecular findings. ( 22505007 )
2012
4
Toona sinensis extracts induced cell cycle arrest and apoptosis in the human lung large cell carcinoma. ( 20123594 )
2010
5
Curcumin inhibits human lung large cell carcinoma cancer tumour growth in a murine xenograft model. ( 20077433 )
2010
6
Lung large cell carcinoma producing granulocyte-colony-stimulating factor. ( 17184692 )
2007
7
Bilateral adrenal metastases from large cell carcinoma of lung in a female non-smoker patient. ( 16912999 )
2006
8
Solitary adrenal metastasis in large cell carcinoma of lung. ( 15558361 )
2004
9
Primary lung large cell carcinoma metastatic to the vulva: a case report and review of the literature. ( 15350382 )
2004
10
Large cell carcinoma of lung with osteoclast-like giant cells. ( 9639130 )
1998
11
High-dose tamoxifen reverses drug resistance to cisplatin and etoposide in a patient with advanced large cell carcinoma of lung. ( 9137495 )
1997
12
Establishment and characterization of a cell line, KaMi, from human lung large cell carcinoma. ( 1279943 )
1992

Variations for Lung Large Cell Carcinoma

Cosmic variations for Lung Large Cell Carcinoma:

9
(show top 50) (show all 1282)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM21262 WNK3 lung,NS,carcinoma,large cell carcinoma c.4599G>T p.L1533F 23:54236967-54236967 15
2 COSM12945 TTBK1 lung,NS,carcinoma,large cell carcinoma c.2417C>T p.S806F 6:43283157-43283157 15
3 COSM12943 TRRAP lung,NS,carcinoma,large cell carcinoma c.8015C>T p.P2672L 7:98976613-98976613 15
4 COSM12942 TRPM6 lung,NS,carcinoma,large cell carcinoma c.3021G>C p.W1007C 9:74782752-74782752 15
5 COSM10808 TP53 lung,NS,carcinoma,large cell carcinoma c.488A>G p.Y163C 17:7675124-7675124 15
6 COSM43963 TP53 lung,NS,carcinoma,large cell carcinoma c.396G>C p.K132N 17:7675216-7675216 15
7 COSM11188 TP53 lung,NS,carcinoma,large cell carcinoma c.412G>C p.A138P 17:7675200-7675200 15
8 COSM10887 TP53 lung,NS,carcinoma,large cell carcinoma c.833C>G p.P278R 17:7673787-7673787 15
9 COSM21593 TP53 lung,NS,carcinoma,large cell carcinoma c.358A>T p.K120* 17:7676011-7676011 15
10 COSM10770 TP53 lung,NS,carcinoma,large cell carcinoma c.1045G>T p.E349* 17:7670664-7670664 15
11 COSM11333 TP53 lung,NS,carcinoma,large cell carcinoma c.499C>T p.Q167* 17:7675113-7675113 15
12 COSM44398 TP53 lung,NS,carcinoma,large cell carcinoma c.682G>A p.D228N 17:7674281-7674281 15
13 COSM10726 TP53 lung,NS,carcinoma,large cell carcinoma c.856G>A p.E286K 17:7673764-7673764 15
14 COSM10659 TP53 lung,NS,carcinoma,large cell carcinoma c.817C>T p.R273C 17:7673803-7673803 15
15 COSM11392 TP53 lung,NS,carcinoma,large cell carcinoma c.800G>C p.R267P 17:7673820-7673820 15
16 COSM10810 TP53 lung,NS,carcinoma,large cell carcinoma c.725G>T p.C242F 17:7674238-7674238 15
17 COSM10648 TP53 lung,NS,carcinoma,large cell carcinoma c.524G>A p.R175H 17:7675088-7675088 15
18 COSM11073 TP53 lung,NS,carcinoma,large cell carcinoma c.1024C>T p.R342* 17:7670685-7670685 15
19 COSM43559 TP53 lung,NS,carcinoma,large cell carcinoma c.517G>T p.V173L 17:7675095-7675095 15
20 COSM10859 TP53 lung,NS,carcinoma,large cell carcinoma c.814G>T p.V272L 17:7673806-7673806 15
21 COSM10941 TP53 lung,NS,carcinoma,large cell carcinoma c.730G>A p.G244S 17:7674233-7674233 15
22 COSM3849376 TP53 lung,NS,carcinoma,large cell carcinoma c.753C>G p.I251M 17:7674210-7674210 15
23 COSM11323 TP53 lung,NS,carcinoma,large cell carcinoma c.482C>A p.A161D 17:7675130-7675130 15
24 COSM44327 TP53 lung,NS,carcinoma,large cell carcinoma c.518T>C p.V173A 17:7675094-7675094 15
25 COSM10654 TP53 lung,NS,carcinoma,large cell carcinoma c.637C>T p.R213* 17:7674894-7674894 15
26 COSM10733 TP53 lung,NS,carcinoma,large cell carcinoma c.574C>T p.Q192* 17:7674957-7674957 15
27 COSM10646 TP53 lung,NS,carcinoma,large cell carcinoma c.725G>A p.C242Y 17:7674238-7674238 15
28 COSM45677 TP53 lung,NS,carcinoma,large cell carcinoma c.714T>A p.C238* 17:7674249-7674249 15
29 COSM44439 TP53 lung,NS,carcinoma,large cell carcinoma c.656C>T p.P219L 17:7674875-7674875 15
30 COSM43947 TP53 lung,NS,carcinoma,large cell carcinoma c.614A>G p.Y205C 17:7674917-7674917 15
31 COSM45675 TP53 lung,NS,carcinoma,large cell carcinoma c.673-1G>C p.? 17:7674291-7674291 15
32 COSM6081949 TP53 lung,NS,carcinoma,large cell carcinoma c.1060C>T p.Q354* 17:7670649-7670649 15
33 COSM10788 TP53 lung,NS,carcinoma,large cell carcinoma c.764T>G p.I255S 17:7674199-7674199 15
34 COSM43626 TP53 lung,NS,carcinoma,large cell carcinoma c.475G>A p.A159T 17:7675137-7675137 15
35 COSM6932 TP53 lung,NS,carcinoma,large cell carcinoma c.733G>A p.G245S 17:7674230-7674230 15
36 COSM44891 TP53 lung,NS,carcinoma,large cell carcinoma c.796G>T p.G266* 17:7673824-7673824 15
37 COSM10750 TP53 lung,NS,carcinoma,large cell carcinoma c.490A>T p.K164* 17:7675122-7675122 15
38 COSM44621 TP53 lung,NS,carcinoma,large cell carcinoma c.718A>T p.S240C 17:7674245-7674245 15
39 COSM11114 TP53 lung,NS,carcinoma,large cell carcinoma c.528C>G p.C176W 17:7675084-7675084 15
40 COSM10687 TP53 lung,NS,carcinoma,large cell carcinoma c.527G>A p.C176Y 17:7675085-7675085 15
41 COSM43549 TP53 lung,NS,carcinoma,large cell carcinoma c.481G>T p.A161S 17:7675131-7675131 15
42 COSM45268 TP53 lung,NS,carcinoma,large cell carcinoma c.827C>A p.A276D 17:7673793-7673793 15
43 COSM44204 TP53 lung,NS,carcinoma,large cell carcinoma c.423C>G p.C141W 17:7675189-7675189 15
44 COSM43568 TP53 lung,NS,carcinoma,large cell carcinoma c.772G>T p.E258* 17:7674191-7674191 15
45 COSM45351 TP53 lung,NS,carcinoma,large cell carcinoma c.434T>G p.L145R 17:7675178-7675178 15
46 COSM44133 TP53 lung,NS,carcinoma,large cell carcinoma c.859G>T p.E287* 17:7673761-7673761 15
47 COSM11514 TP53 lung,NS,carcinoma,large cell carcinoma c.1001G>T p.G334V 17:7670708-7670708 15
48 COSM43779 TP53 lung,NS,carcinoma,large cell carcinoma c.589G>A p.V197M 17:7674942-7674942 15
49 COSM44633 TP53 lung,NS,carcinoma,large cell carcinoma c.583A>T p.I195F 17:7674948-7674948 15
50 COSM43812 TP53 lung,NS,carcinoma,large cell carcinoma c.277C>A p.L93M 17:7676092-7676092 15

Expression for Lung Large Cell Carcinoma

Search GEO for disease gene expression data for Lung Large Cell Carcinoma.

Pathways for Lung Large Cell Carcinoma

Pathways related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.44 ATR DDR2 EPHA3 EPHA5 FGFR1 MTOR
2
Show member pathways
13.34 CAMK4 DDR2 EPHA3 EPHA5 FGFR1 MTOR
3
Show member pathways
13.15 DDR2 EPHA3 EPHA5 FGFR1 MTOR ROS1
4
Show member pathways
13.03 DDR2 EPHA3 EPHA5 FGFR1 MTOR ROS1
5
Show member pathways
12.95 CAMK4 DDR2 EPHA3 EPHA5 FGFR1 MTOR
6
Show member pathways
12.82 CAMK4 DDR2 EPHA3 EPHA5 FGFR1 ROS1
7
Show member pathways
12.6 DDR2 EPHA3 EPHA5 FGFR1 MTOR
8
Show member pathways
12.27 DDR2 EPHA3 EPHA5 FGFR1 MYO18B ROS1
9 11.19 DDR2 EPHA3 EPHA5 FGFR1 ROS1

GO Terms for Lung Large Cell Carcinoma

Cellular components related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.73 BRSK1 CAMK4 DDR2 EPHA3 EPHA5 FGFR1
2 receptor complex GO:0043235 9.02 DDR2 EPHA3 EPHA5 FGFR1 ROS1

Biological processes related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.95 BRSK1 DDR2 EPHA3 EPHA5 FGFR1 ROS1
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.85 DDR2 EPHA3 EPHA5 FGFR1 ROS1
3 positive regulation of MAPK cascade GO:0043410 9.83 DDR2 EPHA3 EPHA5 FGFR1 ROS1
4 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.8 DDR2 EPHA3 EPHA5 ROS1
5 positive regulation of neuron projection development GO:0010976 9.78 EPHA3 FGFR1 MTOR NME1
6 negative regulation of signal transduction GO:0009968 9.77 DDR2 EPHA3 EPHA5 FGFR1 ROS1
7 peptidyl-serine phosphorylation GO:0018105 9.75 ATR CAMK4 MTOR
8 protein autophosphorylation GO:0046777 9.73 ATR CAMK4 DDR2 FGFR1 MTOR WNK3
9 regulation of GTPase activity GO:0043087 9.72 EPHA3 EPHA5 MTOR
10 positive regulation of kinase activity GO:0033674 9.72 DDR2 EPHA3 EPHA5 FGFR1 ROS1
11 regulation of actin cytoskeleton organization GO:0032956 9.7 EPHA3 EPHA5 MTOR
12 protein phosphorylation GO:0006468 9.65 BRSK1 CAMK4 DDR2 EPHA3 EPHA5 FGFR1
13 peptidyl-tyrosine phosphorylation GO:0018108 9.63 DDR2 EPHA3 EPHA5 FGFR1 ROS1 TTN
14 long-term memory GO:0007616 9.58 CAMK4 MTOR
15 regulation of osteoclast differentiation GO:0045670 9.57 CAMK4 MTOR
16 regulation of phosphate transport GO:0010966 9.51 FGFR1 ROS1
17 phosphorylation GO:0016310 9.44 ATR BRSK1 CAMK4 DDR2 EPHA3 EPHA5
18 multicellular organism development GO:0007275 10.03 ATR DDR2 EPHA3 EPHA5 FGFR1 ROS1
19 cell differentiation GO:0030154 10.01 DDR2 EPHA3 EPHA5 FGFR1 NME1 ROS1

Molecular functions related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.97 ATR BRSK1 CAMK4 DDR2 EPHA3 EPHA5
2 protein serine/threonine kinase activity GO:0004674 9.93 ATR BRSK1 CAMK4 MTOR TTN WNK3
3 transmembrane signaling receptor activity GO:0004888 9.88 DDR2 EPHA3 EPHA5 FGFR1 ROS1
4 protein tyrosine kinase activity GO:0004713 9.85 DDR2 EPHA3 EPHA5 FGFR1 ROS1 TTN
5 MAP kinase kinase kinase activity GO:0004709 9.83 DDR2 EPHA3 EPHA5 FGFR1 ROS1
6 mitogen-activated protein kinase kinase binding GO:0031434 9.8 DDR2 EPHA3 EPHA5 FGFR1 ROS1
7 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.72 DDR2 EPHA3 EPHA5 FGFR1 ROS1
8 protein kinase activity GO:0004672 9.7 ATR BRSK1 CAMK4 DDR2 EPHA3 EPHA5
9 gamma-tubulin binding GO:0043015 9.54 BRSK1 NME1
10 transmembrane-ephrin receptor activity GO:0005005 9.52 EPHA3 EPHA5
11 ephrin receptor activity GO:0005003 9.51 EPHA3 EPHA5
12 GPI-linked ephrin receptor activity GO:0005004 9.49 EPHA3 EPHA5
13 kinase activity GO:0016301 9.44 ATR BRSK1 CAMK4 DDR2 EPHA3 EPHA5
14 transferase activity GO:0016740 10.07 ATR BRSK1 CAMK4 DDR2 EPHA3 EPHA5

Sources for Lung Large Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....